Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Alan P. Venook(UCSF Helen Diller Family Comprehensive Cancer Center), Mahmoud M. Al-Hawary(University of Michigan), Nilofer Azad(Sidney Kimmel Comprehensive Cancer Center), Yi‐Jen Chen(City Of Hope National Medical Center), Kristen K. Ciombor(Breast Cancer Research Foundation), Stacey A. Cohen(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Harry S. Cooper(Fox Chase Cancer Center), Dustin A. Deming(University of Wisconsin Carbone Cancer Center), Ignacio Garrido‐Laguna(University of Utah), Jean L. Grem(Susan Thompson Buffett Foundation), Andrew J. Gunn(University of Colorado Cancer Center), J. Randolph Hecht(Moffitt Cancer Center), Sarah E. Hoffe(Moffitt Cancer Center), Joleen M. Hubbard, Steven R. Hunt(Barnes-Jewish Hospital), William R. Jeck(Cancer Institute (WIA)), Kimberly L. Johung(Yale Cancer Center), Natalie Kirilcuk(Cancer Institute (WIA)), Smitha Krishnamurthi(Cleveland Clinic), Jennifer K. Maratt(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Wells A. Messersmith(University of Colorado Cancer Center), Jeffrey A. Meyerhardt(Dana-Farber Brigham Cancer Center), Eric D. Miller(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mary F. Mulcahy(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Steven Nurkin, Michael J. Overman(The University of Texas MD Anderson Cancer Center), Aparna Parikh(Massachusetts General Hospital), Hitendra Patel(University of California San Diego), Katrina S. Pedersen(Barnes-Jewish Hospital), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Charles Schneider(University of Pennsylvania), David Shibata(University of Tennessee Health Science Center), John M. Skibber(The University of Texas MD Anderson Cancer Center), Constantinos T. Sofocleous(Memorial Sloan Kettering Cancer Center), Eden Stotsky‐Himelfarb(Sidney Kimmel Comprehensive Cancer Center), Anna Tavakkoli(Southwestern Medical Center), Christopher G. Willett(Cancer Institute (WIA)), Kristina M. Gregory(National Comprehensive Cancer Network), Lisa A. Gurski(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
October 1, 2022
Cited by 812Open Access
Full Text

Abstract

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a "watch-and-wait" nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org, covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.


Related Papers

No related papers found

Powered by citation graph analysis